Idarubicin

Idarubicin is an orally active and potent anthracycline antileukemic agent. Idarubicin inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin shows induction of DNA damage. Idarubicin inhibits DNA synthesis and of c-myc expression. Idarubicin inhibits the growth of bacteria and yeasts[1][2][3][4][5].

Product Specifications

CAS Number

[58957-92-9]

Product Name Alternative

4-Demethoxydaunorubicin

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Antibiotic; Autophagy; Bacterial; c-Myc; DNA/RNA Synthesis; Fungal; Topoisomerase

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/idarubicin.html

Purity

99.89

Solubility

10 mM in DMSO

Smiles

OC(C(C(C1=CC=CC=C21)=O)=C3C2=O)=C4[C@H](C[C@@](C(C)=O)(O)CC4=C3O)O[C@@](O[C@@H](C)[C@H]5O)([H])C[C@@H]5N

Molecular Formula

C26H27NO9

Molecular Weight

497.49

Precautions

H302, H312, H332

References & Citations

[1]Orlandi P, et al. Idarubicin and idarubicinol effects on breast cancer multicellular spheroids. J Chemother. 2005 Dec;17 (6) :663-7.|[2]Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet. 1993 Apr;24 (4) :275-88.|[3]Siegsmund MJ, et al. Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells. Eur Urol. 1997;31 (3) :365-70.|[4]Gewirtz DA, et al. Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line. Cancer Chemother Pharmacol. 1998;41 (5) :361-|[5]Kinnunen U, et al. Idarubicin inhibits the growth of bacteria and yeasts in an automated blood culture system. Eur J Clin Microbiol Infect Dis. 2009 Mar;28 (3) :301-3.